Eli Lilly & Company (NYSE: LLY) announced a $450 million investment plan to expand its production capacity at its Research Triangle Park (North Carolina) facility, creating at least 100 new jobs. The expansion includes additional parenteral filling, device assembly and packaging capacity to meet growing demand for Lilly’s incretin drugs that treat diabetes.
“In 2023, Lilly will focus on finding innovative solutions to meet the growing demand for our medicines,” said Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations. “The expansion of our operations at the North Carolina Research Park will accelerate the rate at which we can produce drugs to address serious health problems such as diabetes by the end of this year, and this investment will ensure that It is important that more patients have access to the medicines they will need in the future.”
Since 2020, Lilly has invested approximately $4 billion in new manufacturing facilities in North Carolina, including $1.7 billion for the development and expansion of this manufacturing facility. The company expects to begin initial production this year in preparation for US Food and Drug Administration (FDA) inspections.
Since 2014, Lilly has made 18 new medicines available to patients and healthcare professionals to improve the lives of people affected by diseases such as diabetes and cancer, and plans to launch potential new treatments in 2023. This is an important step for expanding supply. Lilly’s current medicines as it prepares to bring the next generation of medicines to patients around the world.
The expansion, which will be fully operational by 2027, will create at least 100 new jobs, primarily for manufacturing personnel who will use advanced technology to produce incretin treatments and medical devices.
As Lilly prepares for an expected surge in potential new drugs to treat diabetes, obesity, Alzheimer’s disease, cancer and autoimmune conditions, the company is looking to further expand its global manufacturing network to ensure a continuous supply of adequate drugs around the world. hopes to